Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652613 | 0.91 | HTT (0.76) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL3006703 | 0.84 | HTT (0.79) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL14565028 | 0.83 | MAOB (0.57) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL8786021 | 0.80 | MAOB (0.61) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL4654145 | 0.78 | ALDH1A1 (0.52) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL9730163 | 0.77 | HTT (0.56) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL13323 | 0.77 | ALDH1A1 (0.60) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL30270528 | 0.77 | HTT (1.00) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL619633 | 0.77 | HTT (1.00) | HTTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL8786235 | 0.77 | MAOB (0.56) | HTTMAOAMAOBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844029-B1 | NOVEL HETEROCYCLIC OXIME DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS HYPOGLYCAEMIC OR HYPOLIPIDEMIC AGENTS | SERVIER LAB (FR) | 2008-11-12 | — | — | EP | disclosed |
| US-20080113974-A1 | Heterocyclic Oxime Compounds, A Process For Their Preparation And Pharmaceutical Compositions Containing Them. | LES LABORATOIRES SERVIER (FR) | 2008-05-15 | — | — | US | disclosed |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | PARALLEL WIRELESS, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | PARALLEL WIRELESS, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113974-A1 | Heterocyclic Oxime Compounds, A Process For Their Preparation And Pharmaceutical Compositions Containing Them. | CBR1, CYP3A7, CYP2C9 | HTT 1780/4885MAOA 67/4885MAOB 26/4885 |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | CYP19A1, CYP17A1, HSD17B11 | HTT 4268/4885MAOA 97/4885MAOB 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.